company background image
SNSE logo

Sensei Biotherapeutics NasdaqGM:SNSE Stock Report

Last Price

US$1.04

Market Cap

US$29.1m

7D

-2.8%

1Y

-21.2%

Updated

26 Mar, 2024

Data

Company Financials +

Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Stock Report

Market Cap: US$29.1m

SNSE Stock Overview

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.

SNSE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Sensei Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sensei Biotherapeutics
Historical stock prices
Current Share PriceUS$1.04
52 Week HighUS$1.93
52 Week LowUS$0.51
Beta0.091
1 Month Change37.75%
3 Month Change49.47%
1 Year Change-21.21%
3 Year Change-91.54%
5 Year Changen/a
Change since IPO-94.50%

Recent News & Updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

SNSEUS BiotechsUS Market
7D-2.8%-0.5%0.6%
1Y-21.2%9.6%29.5%

Return vs Industry: SNSE underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: SNSE underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is SNSE's price volatile compared to industry and market?
SNSE volatility
SNSE Average Weekly Movement10.8%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SNSE's share price has been volatile over the past 3 months.

Volatility Over Time: SNSE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199928John Celebihttps://www.senseibio.com

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company’s pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.

Sensei Biotherapeutics, Inc. Fundamentals Summary

How do Sensei Biotherapeutics's earnings and revenue compare to its market cap?
SNSE fundamental statistics
Market capUS$29.08m
Earnings (TTM)-US$34.10m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNSE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$34.10m
Earnings-US$34.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SNSE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.